Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B. (Q35610571)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22180724%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22180724%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22180724%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

3

Alan S Perelson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22180724%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1

Harel Dahari

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22180724%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Thomas J Layden

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22180724%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

language of work or name

1 reference

1 July 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22180724%20AND%20SRC:MED&resulttype=core&format=json

Current hepatitis reports

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22180724%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22180724%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22180724%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

214-227

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22180724%20AND%20SRC:MED&resulttype=core&format=json

Potential treatment options and future research to increase hepatitis C virus treatment response rate

18 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Hepatocyte proliferation and hepatitis C virus kinetics during treatment

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Cell-based hepatitis C virus infection fluorescence resonance energy transfer (FRET) assay for antiviral compound screening

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

A perspective on modelling hepatitis C virus infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

The recent breakthroughs in the understanding of host genomics in hepatitis C.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Rapid emergence of protease inhibitor resistance in hepatitis C virus

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Telaprevir for previously treated chronic HCV infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Resistance to direct antiviral agents in patients with hepatitis C virus infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

The Evolution of the Major Hepatitis C Genotypes Correlates with Clinical Response to Interferon Therapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Antiviral resistance and specifically targeted therapy for HCV (STAT-C).

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Modeling Subgenomic Hepatitis C Virus RNA Kinetics during Treatment with Alpha Interferon

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

ANALYSIS OF HEPATITIS C VIRUS INFECTION MODELS WITH HEPATOCYTE HOMEOSTASIS

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Hepatitis C Viral Kinetics in Special Populations

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Modeling hepatitis C virus dynamics: Liver regeneration and critical drug efficacy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Unravelling hepatitis C virus replication from genome to function

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Complete replication of hepatitis C virus in cell culture

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Robust hepatitis C virus infection in vitro

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Antiviral action of ribavirin in chronic hepatitis C.

12 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Triphasic decline of hepatitis C virus RNA during antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

A comprehensive hepatitis C viral kinetic model explaining cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Impact of IL-28B SNPs on control of hepatitis C virus infection: a genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

High sensitivity assay using serum sample for IL28B genotyping to predict treatment response in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

First phase hepatitis c viral kinetics in previous nonresponders patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Modelling how ribavirin improves interferon response rates in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11901-011-0101-7

Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Rapid decrease of wild-type hepatitis C virus on telaprevir treatment.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3237049

10.1007/S11901-011-0101-7

25 September 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22180724%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22180724%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22180724%20AND%20SRC:MED&resulttype=core&format=json